View ValuationJeevan Scientific Technology 将来の成長Future 基準チェック /06現在、 Jeevan Scientific Technologyの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Life Sciences 収益成長23.7%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • May 31Full year 2026 earnings released: EPS: ₹0.52 (vs ₹0.085 in FY 2025)Full year 2026 results: EPS: ₹0.52 (up from ₹0.085 in FY 2025). Revenue: ₹625.1m (up 33% from FY 2025). Net income: ₹11.5m (up ₹10.2m from FY 2025). Profit margin: 1.8% (up from 0.3% in FY 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth.Reported Earnings • Feb 14Third quarter 2026 earnings released: EPS: ₹1.52 (vs ₹0.062 in 3Q 2025)Third quarter 2026 results: EPS: ₹1.52 (up from ₹0.062 in 3Q 2025). Revenue: ₹190.7m (up 53% from 3Q 2025). Net income: ₹14.2m (up ₹13.2m from 3Q 2025). Profit margin: 7.5% (up from 0.8% in 3Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.Reported Earnings • Nov 13Second quarter 2026 earnings released: EPS: ₹0.01 (vs ₹0.16 in 2Q 2025)Second quarter 2026 results: EPS: ₹0.01 (down from ₹0.16 in 2Q 2025). Revenue: ₹125.8m (up 10% from 2Q 2025). Net loss: ₹875.0k (down 137% from profit in 2Q 2025). Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.お知らせ • Oct 17Jeevan Scientific Technology Limited announced that it expects to receive INR 202.4 million in funding from Decibels Properties Private Limited, Padmaja Private Trust, Synfinx Capital Private Limited, Tradewell Capfin Private Limited an other investors.Jeevan Scientific Technology Limited announced a private placement to issue 3,500,000 Convertible Warrants at an issue price of INR 10 for the proceeds of INR 35,000,000 and 4,185,000 Equity shares at an issue price of INR 40 for the proceeds of INR 167,400,000 on October 15, 2025. The transaction involves participation of Krishna Kishore Kuchipudi for 1,200,000 warrant, K Vanaja for 600,000 , Jeevan Krishna Kuchipudi for 600,000, Padmaja Private Trust for 1,500,000 shares, Pranali Bangad for 300,000 shares, Sushma Bangad for 300,000 shares and other investors. The transaction is approved by board of directors and is subject to shareholder and regulatory approval. The warrants are exercisable within 18 months from the date of allotment at INR 30.New Risk • Oct 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 35% per year over the past 5 years. Market cap is less than US$10m (₹834.0m market cap, or US$9.41m). Minor Risks High level of debt (41% net debt to equity). Share price has been volatile over the past 3 months (7.3% average weekly change). Revenue is less than US$5m (₹428m revenue, or US$4.8m).お知らせ • Sep 08Jeevan Scientific Technology Limited, Annual General Meeting, Sep 27, 2025Jeevan Scientific Technology Limited, Annual General Meeting, Sep 27, 2025, at 10:00 Indian Standard Time.お知らせ • Sep 05+ 1 more updateJeevan Scientific Technology Limited to Report Q4, 2026 Results on May 30, 2026Jeevan Scientific Technology Limited announced that they will report Q4, 2026 results on May 30, 2026Reported Earnings • Aug 16First quarter 2026 earnings released: ₹2.03 loss per share (vs ₹0.66 profit in 1Q 2025)First quarter 2026 results: ₹2.03 loss per share (down from ₹0.66 profit in 1Q 2025). Revenue: ₹91.3m (down 29% from 1Q 2025). Net loss: ₹31.0m (down 385% from profit in 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 61 percentage points per year, which is a significant difference in performance.お知らせ • Aug 02Jeevan Scientific Technology Limited to Report Q1, 2026 Results on Aug 07, 2025Jeevan Scientific Technology Limited announced that they will report Q1, 2026 results on Aug 07, 2025Reported Earnings • Jun 02Full year 2025 earnings released: EPS: ₹0.04 (vs ₹0.84 loss in FY 2024)Full year 2025 results: EPS: ₹0.04 (up from ₹0.84 loss in FY 2024). Revenue: ₹475.0m (up 20% from FY 2024). Net income: ₹1.34m (up ₹14.3m from FY 2024). Profit margin: 0.3% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 78 percentage points per year, which is a significant difference in performance.お知らせ • May 26Jeevan Scientific Technology Limited to Report Q4, 2025 Results on May 30, 2025Jeevan Scientific Technology Limited announced that they will report Q4, 2025 results on May 30, 2025Board Change • Apr 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 3 highly experienced directors. Independent Director Divakar Atluri was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.New Risk • Mar 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹698.8m market cap, or US$8.03m). Minor Risk Share price has been volatile over the past 3 months (8.1% average weekly change).Reported Earnings • Feb 07Third quarter 2025 earnings released: EPS: ₹0.03 (vs ₹0.31 loss in 3Q 2024)Third quarter 2025 results: EPS: ₹0.03 (up from ₹0.31 loss in 3Q 2024). Revenue: ₹127.4m (up 26% from 3Q 2024). Net income: ₹1.05m (up ₹5.82m from 3Q 2024). Profit margin: 0.8% (up from net loss in 3Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 69 percentage points per year, which is a significant difference in performance.お知らせ • Feb 06Jeevan Scientific Technology Limited Appoints Venkateswara Rao Ravipati as Chief Financial OfficerJeevan Scientific Technology Limited at its board meeting held on February 6, 2025, approved appointment of Mr. Venkateswara Rao Ravipati as Chief Financial Officer of the Company with effect from February 6, 2025. Mr. Venkateswara Rao Ravipati has 20+ years of experience in Accounts, Tax and Finance function. Mr. Venkateswara Rao Ravipati is a Commerce Post Graduate with 20+ years of extensive experience in finance, GST laws, Income Tax Laws, Budget Preparation, Finalization of Quarterly and Annual Accounts, Preparation of financials for Internal & Statutory Audits, Timely preparation of all Monthly, Quarterly and Annual accounts, Books of accounts maintained as per various Accounting Standards and Company policies from time to time.お知らせ • Jan 30Jeevan Scientific Technology Limited to Report Q3, 2025 Results on Feb 06, 2025Jeevan Scientific Technology Limited announced that they will report Q3, 2025 results on Feb 06, 2025お知らせ • Nov 27Jeevan Scientific Technology Limited Announces Cessation of G. Siva Nageswara Rao as Chief Financial OfficerJeevan Scientific Technology Limited announced the cessation of G. Siva Nageswara Rao as Chief Financial Officer of the Company with effect from November 25, 2024, due to personal reasons.New Risk • Nov 11New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (2.3% increase in shares outstanding). Market cap is less than US$100m (₹856.5m market cap, or US$10.1m).Reported Earnings • Nov 10Second quarter 2025 earnings released: EPS: ₹0.16 (vs ₹0.39 loss in 2Q 2024)Second quarter 2025 results: EPS: ₹0.16 (up from ₹0.39 loss in 2Q 2024). Revenue: ₹115.6m (up 43% from 2Q 2024). Net income: ₹2.39m (up ₹8.40m from 2Q 2024). Profit margin: 2.1% (up from net loss in 2Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 92 percentage points per year, which is a significant difference in performance.お知らせ • Nov 08+ 2 more updatesJeevan Scientific Technology Limited Approves Chief Executive Officer ChangesJeevan Scientific Technology Limited at its meeting held on November 08, 2024 approved the following items of business: Resignation of Mrs. Snigdha Mothukuri as Chief Executive Officer of the Company with effect from November 08, 2024. However, she will continue as Executive Director with additional management powers and responsibilities. Appointment of Dr. Srinivas Reddy Maram as Chief Executive Officer of the Company with effect from November 08, 2024. Dr. Srinivas Reddy comes with over 26+ years of experience in Pharmaceutical Industry -- Education: Dr. Srinivas has done his MSC and PhD in Chemistry from Andhra University and also done his Senior Management program from IIM Calcutta. He has proven track record in driving business growth through strategic marketing Initiatives and financial acumen. He is expert in navigating complex regulatory environments, while implementing operational efficiencies that enhance CRO Business and product development and client engagements. He is a committed in delivering sustainable growth and elevating organizational performance through visionary leadership and strategic partnerships. He has earlier worked for organizations like Actimus Bioscience Elmira, Zydus Healthcare, lifesciences, Strides Arcolab, Dr. Reddys.お知らせ • Nov 02Jeevan Scientific Technology Limited to Report Q2, 2025 Results on Nov 08, 2024Jeevan Scientific Technology Limited announced that they will report Q2, 2025 results on Nov 08, 2024New Risk • Oct 04New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹837.9m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.Reported Earnings • Aug 13First quarter 2025 earnings released: EPS: ₹0.66 (vs ₹0.33 in 1Q 2024)First quarter 2025 results: EPS: ₹0.66 (up from ₹0.33 in 1Q 2024). Revenue: ₹128.8m (up 24% from 1Q 2024). Net income: ₹10.9m (up 112% from 1Q 2024). Profit margin: 8.5% (up from 5.0% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 97 percentage points per year, which is a significant difference in performance.お知らせ • Aug 03Jeevan Scientific Technology Limited to Report Q1, 2025 Results on Aug 09, 2024Jeevan Scientific Technology Limited announced that they will report Q1, 2025 results on Aug 09, 2024Reported Earnings • Jun 05Full year 2024 earnings released: ₹0.86 loss per share (vs ₹2.00 loss in FY 2023)Full year 2024 results: ₹0.86 loss per share (improved from ₹2.00 loss in FY 2023). Revenue: ₹403.3m (up 12% from FY 2023). Net loss: ₹13.0m (loss narrowed 58% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 77 percentage points per year, which is a significant difference in performance.お知らせ • May 31Jeevan Scientific Technology Limited, Annual General Meeting, Aug 09, 2024Jeevan Scientific Technology Limited, Annual General Meeting, Aug 09, 2024, at 10:00 Indian Standard Time.お知らせ • May 23Jeevan Scientific Technology Limited to Report Q4, 2024 Results on May 30, 2024Jeevan Scientific Technology Limited announced that they will report Q4, 2024 results on May 30, 2024お知らせ • Mar 13Jeevan Scientific Technology Limited Announces Executive Changes, Effective March 31, 2024Jeevan Scientific Technology Limited announced that Mrs. Sharvari Swapnil Shinde has resigned from the post of Company Secretary and Compliance Officer of company with effect from March 31, 2024 (After close of business hours). Mr. Krishna Kishore Kuchipudi, Managing Director of the Company will act as Compliance officer of the Company till the appointment of new Company Secretary and Compliance Officer.Reported Earnings • Feb 15Third quarter 2024 earnings released: ₹0.31 loss per share (vs ₹0.04 profit in 3Q 2023)Third quarter 2024 results: ₹0.31 loss per share (down from ₹0.04 profit in 3Q 2023). Revenue: ₹100.1m (flat on 3Q 2023). Net loss: ₹4.77m (down ₹5.31m from profit in 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance.お知らせ • Feb 07Jeevan Scientific Technology Limited to Report Q3, 2024 Results on Feb 14, 2024Jeevan Scientific Technology Limited announced that they will report Q3, 2024 results on Feb 14, 2024Reported Earnings • Nov 15Second quarter 2024 earnings released: ₹0.39 loss per share (vs ₹0.83 loss in 2Q 2023)Second quarter 2024 results: ₹0.39 loss per share (improved from ₹0.83 loss in 2Q 2023). Revenue: ₹83.2m (up 4.4% from 2Q 2023). Net loss: ₹6.02m (loss narrowed 50% from 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has increased by 21% per year, which means it is well ahead of earnings.お知らせ • Nov 05Jeevan Scientific Technology Limited to Report Q2, 2024 Results on Nov 13, 2023Jeevan Scientific Technology Limited announced that they will report Q2, 2024 results on Nov 13, 2023New Risk • Oct 26New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹830.2m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Market cap is less than US$10m (₹830.2m market cap, or US$9.97m). Minor Risk Revenue is less than US$5m (₹362m revenue, or US$4.4m).Reported Earnings • Aug 16First quarter 2024 earnings released: EPS: ₹0.33 (vs ₹0.26 in 1Q 2023)First quarter 2024 results: EPS: ₹0.33 (up from ₹0.26 in 1Q 2023). Revenue: ₹106.9m (up 3.5% from 1Q 2023). Net income: ₹5.15m (up 35% from 1Q 2023). Profit margin: 4.8% (up from 3.7% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 45% per year, which means it is well ahead of earnings.お知らせ • Aug 15Jeevan Scientific Technology Limited, Annual General Meeting, Sep 29, 2023Jeevan Scientific Technology Limited, Annual General Meeting, Sep 29, 2023, at 10:30 Indian Standard Time.お知らせ • Aug 12Jeevan Scientific Technology Limited Announces Resignation of Rama Krishna Prasad Kakarala as Non- Executive DirectorJeevan Scientific Technology Limited informed the Exchange that Mr. Rama Krishna Prasad Kakarala (DIN: 00754823), Non- Executive Director of the Company has resigned from the Board of Directors with effect from 12 August, 2023 citing the reason as personal pre occupations and commitments.お知らせ • Aug 08Jeevan Scientific Technology Limited to Report Q1, 2024 Results on Aug 14, 2023Jeevan Scientific Technology Limited announced that they will report Q1, 2024 results on Aug 14, 2023New Risk • Jul 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Revenue is less than US$5m (₹373m revenue, or US$4.5m). Market cap is less than US$100m (₹873.7m market cap, or US$10.6m).Reported Earnings • Feb 09Third quarter 2023 earnings released: EPS: ₹0.04 (vs ₹2.80 in 3Q 2022)Third quarter 2023 results: EPS: ₹0.04 (down from ₹2.80 in 3Q 2022). Revenue: ₹102.3m (down 51% from 3Q 2022). Net income: ₹545.0k (down 99% from 3Q 2022). Profit margin: 0.5% (down from 20% in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has only increased by 37% per year, which means it is significantly lagging earnings growth.お知らせ • Feb 02Jeevan Scientific Technology Limited to Report Q3, 2023 Results on Feb 08, 2023Jeevan Scientific Technology Limited announced that they will report Q3, 2023 results on Feb 08, 2023Recent Insider Transactions • Dec 13CFO & Executive Director recently bought ₹1.1m worth of stockOn the 9th of December, Jeevan Kuchipudi bought around 18k shares on-market at roughly ₹64.97 per share. This transaction amounted to 2.9% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Jeevan's only on-market trade for the last 12 months.Reported Earnings • Nov 16Second quarter 2023 earnings released: ₹0.83 loss per share (vs ₹2.45 profit in 2Q 2022)Second quarter 2023 results: ₹0.83 loss per share (down from ₹2.45 profit in 2Q 2022). Revenue: ₹82.8m (down 56% from 2Q 2022). Net loss: ₹11.9m (down 132% from profit in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 81% per year but the company’s share price has only increased by 41% per year, which means it is significantly lagging earnings growth.Board Change • Nov 16High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Additional Independent Director Suryaprakasa Bommisetti was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 13Second quarter 2023 earnings released: ₹0.83 loss per share (vs ₹2.45 profit in 2Q 2022)Second quarter 2023 results: ₹0.83 loss per share (down from ₹2.45 profit in 2Q 2022). Revenue: ₹82.8m (down 56% from 2Q 2022). Net loss: ₹11.9m (down 132% from profit in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 81% per year but the company’s share price has only increased by 55% per year, which means it is significantly lagging earnings growth.お知らせ • Nov 05Jeevan Scientific Technology Limited to Report Q2, 2023 Results on Nov 11, 2022Jeevan Scientific Technology Limited announced that they will report Q2, 2023 results on Nov 11, 2022Valuation Update With 7 Day Price Move • Oct 10Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹69.25, the stock trades at a trailing P/E ratio of 11.8x. Average trailing P/E is 37x in the Life Sciences industry in India. Total returns to shareholders of 273% over the past three years.お知らせ • Sep 30Jeevan Scientific Technology Limited Declares Dividend for the Financial Year Ended March 31, 2022Jeevan Scientific Technology Limited at the AGM, the shareholders declared dividend of 12% i.e., INR 1.20 per equity share of INR 10 each for the financial year ended 31st March 2022.Upcoming Dividend • Sep 13Upcoming dividend of ₹1.20 per shareEligible shareholders must have bought the stock before 20 September 2022. Payment date: 29 October 2022. Payout ratio is a comfortable 20% and this is well supported by cash flows. Trailing yield: 1.7%. Within top quartile of Indian dividend payers (1.5%). Higher than average of industry peers (0.7%).Valuation Update With 7 Day Price Move • Sep 06Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹63.95, the stock trades at a trailing P/E ratio of 6.5x. Average trailing P/E is 42x in the Life Sciences industry in India. Total returns to shareholders of 247% over the past three years.Valuation Update With 7 Day Price Move • Aug 22Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₹57.95, the stock trades at a trailing P/E ratio of 5.8x. Average trailing P/E is 37x in the Life Sciences industry in India. Total returns to shareholders of 205% over the past three years.お知らせ • Aug 13+ 2 more updatesJeevan Scientific Technology Limited Announces Executive Changes, Effective September 16, 2022Jeevan Scientific Technology Limited announced that at its board meeting held on August 12, 2022, approved the resignation of Mr. Srikanth Sasidhar Mathamsetty, Chief Financial Officer of the company with effect from September 16, 2022; approved the appointment of Mr. K. Jeevan Krishna as Chief Financial Officer of the company with effect from September 16, 2022.お知らせ • Aug 06Jeevan Scientific Technology Limited to Report Q1, 2023 Results on Aug 12, 2022Jeevan Scientific Technology Limited announced that they will report Q1, 2023 results on Aug 12, 2022お知らせ • Aug 05Jeevan Scientific Technology Limited Appoints Chakrapani Majumdar as Chief Operating OfficerJeevan Scientific Technology Limited appointed Mr. Chakrapani Majumdar as Chief Operating Officer of the Company with effect from 03 August 2022. Chakrapani holds Masters in Pharmaceutical Sciences with specialization in Pharmacology, Pharmaceutical Analysis and Biostatistics. Chakrapani comes with 22+ years of collective Operations and Quality Assurance experience working for various pharmaceutical companies and CROs, spanning Bioequivalence studies, Phase-1 to Phase-4 Clinical trials to techno commercial management of CROs. Chakrapani has an accomplished Quality Assurance career and rich experience of facilitating more than 50 Regulatory inspections from various regulatory bodies including USFDA, UK-MHRA, WHO ANSM, ANVISA, AGES, MCC, NPCB, GHC, DCGI etc, His success stories include, setting up of complete QMS and integration of various Global establishments of Veeda CR in India, Malaysia, Belgium, France, USA and UK.Valuation Update With 7 Day Price Move • Jul 28Investor sentiment improved over the past weekAfter last week's 22% share price gain to ₹79.15, the stock trades at a trailing P/E ratio of 8x. Average trailing P/E is 34x in the Life Sciences industry in India. Total returns to shareholders of 266% over the past three years.お知らせ • Jul 07Jeevan Scientific Technology Limited Announces Resignation of Srikanth Sasidhar as Chief Financial OfficerJeevan Scientific Technology Limited informed that Mr. M. Srikanth Sasidhar, CFO has vide letter dated 06.07.2022 has tendered his resignation from the post of Chief Financial Officer which is subject to the approval of the Board in its next meeting.Valuation Update With 7 Day Price Move • Jun 03Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₹69.05, the stock trades at a trailing P/E ratio of 7x. Average trailing P/E is 32x in the Life Sciences industry in India. Total returns to shareholders of 151% over the past three years.お知らせ • May 31Jeevan Scientific Technology Limited Recommends Final DividendJeevan Scientific Technology Limited at the Board Meeting held on 30-May-2022 the company recommended a Final Dividend of INR 1.20 per share subject to approval of members at the upcoming Annual General Meeting.お知らせ • May 20Jeevan Scientific Technology Limited to Report Q4, 2022 Results on May 30, 2022Jeevan Scientific Technology Limited announced that they will report Q4, 2022 results on May 30, 2022Valuation Update With 7 Day Price Move • Apr 29Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₹106, the stock trades at a trailing P/E ratio of 10.7x. Average trailing P/E is 37x in the Life Sciences industry in India. Total returns to shareholders of 247% over the past three years.Board Change • Apr 27High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Additional Independent Director Suryaprakasa Bommisetti was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Buying Opportunity • Apr 18Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 29%. The fair value is estimated to be ₹182, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 43% over the last 3 years. Earnings per share has grown by 87%.Valuation Update With 7 Day Price Move • Apr 06Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹156, the stock trades at a trailing P/E ratio of 15.7x. Average trailing P/E is 37x in the Life Sciences industry in India. Total returns to shareholders of 402% over the past three years.Board Change • Apr 02High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Additional Independent Director Suryaprakasa Bommisetti was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Buying Opportunity • Mar 23Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 9.5%. The fair value is estimated to be ₹181, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 43% per annum over the last 3 years. Earnings per share has grown by 87% per annum over the last 3 years.Valuation Update With 7 Day Price Move • Mar 14Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹144, the stock trades at a trailing P/E ratio of 14.5x. Average trailing P/E is 36x in the Life Sciences industry in India. Total returns to shareholders of 327% over the past three years.Buying Opportunity • Feb 22Now 24% undervaluedOver the last 90 days, the stock is up 25%. The fair value is estimated to be ₹184, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 43% per annum over the last 3 years. Earnings per share has grown by 87% per annum over the last 3 years.Valuation Update With 7 Day Price Move • Feb 21Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₹148, the stock trades at a trailing P/E ratio of 14.9x. Average trailing P/E is 37x in the Life Sciences industry in India. Total returns to shareholders of 346% over the past three years.Reported Earnings • Feb 17Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹2.80 (down from ₹3.74 in 3Q 2021). Revenue: ₹210.2m (up 33% from 3Q 2021). Net income: ₹42.7m (down 26% from 3Q 2021). Profit margin: 20% (down from 36% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has only increased by 70% per year, which means it is significantly lagging earnings growth.お知らせ • Feb 15Jeevan Scientific Technology Limited Approves the Change in Designation of Jeevan Krishna Kuchipudi from Non-Executive Director to Executive DirectorJeevan Scientific Technology Limited at its board meeting held on February 14, 2022 approved the Change in designation of Mr. Jeevan Krishna Kuchipudi from Non-Executive Director to Executive Director with effect from February 14, 2022.お知らせ • Feb 05Jeevan Scientific Technology Limited to Report Q3, 2022 Results on Feb 14, 2022Jeevan Scientific Technology Limited announced that they will report Q3, 2022 results on Feb 14, 2022Valuation Update With 7 Day Price Move • Dec 29Investor sentiment improved over the past weekAfter last week's 21% share price gain to ₹184, the stock trades at a trailing P/E ratio of 16.9x. Average trailing P/E is 33x in the Life Sciences industry in India. Total returns to shareholders of 406% over the past three years.Valuation Update With 7 Day Price Move • Dec 14Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₹162, the stock trades at a trailing P/E ratio of 14.9x. Average trailing P/E is 32x in the Life Sciences industry in India. Total returns to shareholders of 355% over the past three years.Valuation Update With 7 Day Price Move • Nov 25Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₹123, the stock trades at a trailing P/E ratio of 11.4x. Average trailing P/E is 28x in the Life Sciences industry in India. Total returns to shareholders of 263% over the past three years.Reported Earnings • Nov 12Second quarter 2022 earnings released: EPS ₹2.45 (vs ₹1.79 in 2Q 2021)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2022 results: Revenue: ₹189.8m (up 55% from 2Q 2021). Net income: ₹37.4m (up 36% from 2Q 2021). Profit margin: 20% (down from 22% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has only increased by 42% per year, which means it is significantly lagging earnings growth.Reported Earnings • Aug 11First quarter 2022 earnings released: EPS ₹2.17 (vs ₹0.37 loss in 1Q 2021)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: ₹162.9m (up 226% from 1Q 2021). Net income: ₹33.2m (up ₹39.0m from 1Q 2021). Profit margin: 20% (up from net loss in 1Q 2021). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 47% per year whereas the company’s share price has increased by 49% per year.Board Change • Jul 31High number of new directorsCEO & Executive Director Snigdha Mothukuri was the last director to join the board, commencing their role in 2021.Reported Earnings • Jun 26Full year 2021 earnings released: EPS ₹7.71 (vs ₹5.61 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹493.5m (up 98% from FY 2020). Net income: ₹117.4m (up ₹203.3m from FY 2020). Profit margin: 24% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 41% per year, which means it is tracking significantly ahead of earnings growth.Executive Departure • Jun 25CEO & Whole-Time Executive Director Rajendra Muppavarapu has left the companyDuring their tenure, earnings grew by 18% annually compared to the industry average of 9.6%. On the 23rd of June, Rajendra Muppavarapu left the company after 7.2 in the role. Rajendra still personally held 896.25k shares (₹55m worth) as of March 2021. This is 5.9% of the company. Rajendra is the only executive to leave the company over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model. Under Rajendra's leadership, the company delivered a total shareholder return of 170%.Valuation Update With 7 Day Price Move • Jun 09Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹108, the stock trades at a trailing P/E ratio of 69.9x. Average trailing P/E is 57x in the Life Sciences industry in India. Total returns to shareholders of 214% over the past three years.お知らせ • Feb 19Jeevan Scientific Technology Limited Announces Chief Financial Officer ChangesJeevan Scientific Technology Limited announced that Mr. Krishna Kishore Kuchipudi has resigned and ceased to be the Chief Financial Officer of the Company with effect from February 02, 2021. The company announced the appointment of Mr. M. Srikanth Sasidhar as new Chief Financial Officer on Board.Valuation Update With 7 Day Price Move • Feb 03Investor sentiment improved over the past weekAfter last week's 27% share price gain to ₹55.70, the stock is trading at a trailing P/E ratio of 36.1x, up from the previous P/E ratio of 28.3x. This compares to an average P/E of 30x in the Life Sciences industry in India. Total returns to shareholders over the past three years are 24%.Reported Earnings • Jan 28Third quarter 2021 earnings released: EPS ₹3.74 (vs ₹0.26 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₹160.2m (up 90% from 3Q 2020). Net income: ₹57.3m (up ₹53.4m from 3Q 2020). Profit margin: 36% (up from 4.6% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 66% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.Is New 90 Day High Low • Jan 20New 90-day high: ₹39.15The company is up 65% from its price of ₹23.75 on 22 October 2020. The Indian market is up 23% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 15% over the same period.お知らせ • Jan 19Jeevan Scientific Technology Limited to Report Q3, 2021 Results on Jan 27, 2021Jeevan Scientific Technology Limited announced that they will report Q3, 2021 results on Jan 27, 2021Is New 90 Day High Low • Dec 04New 90-day high: ₹35.05The company is up 75% from its price of ₹20.05 on 04 September 2020. The Indian market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 15% over the same period.お知らせ • Nov 25Jeevan Scientific Technology Limited Appoints Ms. Sharvari Swapnil Shinde as the Company Secretary Cum Compliance OfficerJeevan Scientific Technology Limited announced that Ms. Sharvari Swapnil Shinde has been appointed as the company secretary cum Compliance Officer of the company, with effect from November 24, 2020 and she will be responsible for all functions of a Company Secretary as prescribed under Section 203 of the Companies Act, 2013.Is New 90 Day High Low • Nov 04New 90-day high: ₹26.55The company is up 21% from its price of ₹21.95 on 06 August 2020. The Indian market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 15% over the same period.Is New 90 Day High Low • Oct 12New 90-day high: ₹25.25The company is up 36% from its price of ₹18.50 on 14 July 2020. The Indian market is up 10.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Life Sciences industry, which is up 39% over the same period.Is New 90 Day High Low • Sep 24New 90-day high: ₹22.45The company is up 16% from its price of ₹19.30 on 26 June 2020. The Indian market is up 8.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Life Sciences industry, which is up 35% over the same period.お知らせ • Sep 12Jeevan Scientific Technology Limited to Report Q4, 2020 Results on Jul 30, 2020Jeevan Scientific Technology Limited announced that they will report Q4, 2020 results on Jul 30, 2020 このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Jeevan Scientific Technology は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測BSE:538837 - アナリストの将来予測と過去の財務データ ( )INR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/202661512-784N/A12/31/2025503-19N/AN/AN/A9/30/2025437-44-895N/A6/30/2025428-41N/AN/AN/A3/31/20254681-60101N/A12/31/20244797N/AN/AN/A9/30/20244551-6549N/A6/30/2024421-7N/AN/AN/A3/31/2024397-13-9129N/A12/31/2023365-29N/AN/AN/A9/30/2023363-23-131-28N/A6/30/2023362-29N/AN/AN/A3/31/2023362-30-146-64N/A12/31/2022402-1N/AN/AN/A9/30/20225124185162N/A6/30/202261990N/AN/AN/A3/31/2022685119172196N/A12/31/2021703152N/AN/AN/A9/30/2021651166137148N/A6/30/2021596156N/AN/AN/A3/31/20214751174149N/A12/31/202041124N/AN/AN/A9/30/2020337-291424N/A6/30/2020267-71N/AN/AN/A3/31/2020249-86-200N/A12/31/2019212-46N/AN/AN/A9/30/2019208-42N/A33N/A6/30/2019232-14N/AN/AN/A3/31/201926111N/A40N/A12/31/201826125N/AN/AN/A9/30/201823918N/AN/AN/A6/30/20182135N/AN/AN/A3/31/20182041N/A56N/A12/31/20172147N/AN/AN/A9/30/20172008N/AN/AN/A6/30/20171898N/AN/AN/A3/31/20171829N/A-56N/A12/31/2016167-7N/AN/AN/A9/30/2016171-7N/AN/AN/A6/30/2016175-3N/AN/AN/A4/1/20161740N/A35N/A12/31/201516715N/AN/AN/A9/30/201515315N/AN/AN/A6/30/201514718N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 538837の予測収益成長が 貯蓄率 ( 6.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 538837の収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 538837の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 538837の収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 538837の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 538837の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/24 16:11終値2026/06/24 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Jeevan Scientific Technology Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • May 31Full year 2026 earnings released: EPS: ₹0.52 (vs ₹0.085 in FY 2025)Full year 2026 results: EPS: ₹0.52 (up from ₹0.085 in FY 2025). Revenue: ₹625.1m (up 33% from FY 2025). Net income: ₹11.5m (up ₹10.2m from FY 2025). Profit margin: 1.8% (up from 0.3% in FY 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Feb 14Third quarter 2026 earnings released: EPS: ₹1.52 (vs ₹0.062 in 3Q 2025)Third quarter 2026 results: EPS: ₹1.52 (up from ₹0.062 in 3Q 2025). Revenue: ₹190.7m (up 53% from 3Q 2025). Net income: ₹14.2m (up ₹13.2m from 3Q 2025). Profit margin: 7.5% (up from 0.8% in 3Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.
Reported Earnings • Nov 13Second quarter 2026 earnings released: EPS: ₹0.01 (vs ₹0.16 in 2Q 2025)Second quarter 2026 results: EPS: ₹0.01 (down from ₹0.16 in 2Q 2025). Revenue: ₹125.8m (up 10% from 2Q 2025). Net loss: ₹875.0k (down 137% from profit in 2Q 2025). Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.
お知らせ • Oct 17Jeevan Scientific Technology Limited announced that it expects to receive INR 202.4 million in funding from Decibels Properties Private Limited, Padmaja Private Trust, Synfinx Capital Private Limited, Tradewell Capfin Private Limited an other investors.Jeevan Scientific Technology Limited announced a private placement to issue 3,500,000 Convertible Warrants at an issue price of INR 10 for the proceeds of INR 35,000,000 and 4,185,000 Equity shares at an issue price of INR 40 for the proceeds of INR 167,400,000 on October 15, 2025. The transaction involves participation of Krishna Kishore Kuchipudi for 1,200,000 warrant, K Vanaja for 600,000 , Jeevan Krishna Kuchipudi for 600,000, Padmaja Private Trust for 1,500,000 shares, Pranali Bangad for 300,000 shares, Sushma Bangad for 300,000 shares and other investors. The transaction is approved by board of directors and is subject to shareholder and regulatory approval. The warrants are exercisable within 18 months from the date of allotment at INR 30.
New Risk • Oct 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 35% per year over the past 5 years. Market cap is less than US$10m (₹834.0m market cap, or US$9.41m). Minor Risks High level of debt (41% net debt to equity). Share price has been volatile over the past 3 months (7.3% average weekly change). Revenue is less than US$5m (₹428m revenue, or US$4.8m).
お知らせ • Sep 08Jeevan Scientific Technology Limited, Annual General Meeting, Sep 27, 2025Jeevan Scientific Technology Limited, Annual General Meeting, Sep 27, 2025, at 10:00 Indian Standard Time.
お知らせ • Sep 05+ 1 more updateJeevan Scientific Technology Limited to Report Q4, 2026 Results on May 30, 2026Jeevan Scientific Technology Limited announced that they will report Q4, 2026 results on May 30, 2026
Reported Earnings • Aug 16First quarter 2026 earnings released: ₹2.03 loss per share (vs ₹0.66 profit in 1Q 2025)First quarter 2026 results: ₹2.03 loss per share (down from ₹0.66 profit in 1Q 2025). Revenue: ₹91.3m (down 29% from 1Q 2025). Net loss: ₹31.0m (down 385% from profit in 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 61 percentage points per year, which is a significant difference in performance.
お知らせ • Aug 02Jeevan Scientific Technology Limited to Report Q1, 2026 Results on Aug 07, 2025Jeevan Scientific Technology Limited announced that they will report Q1, 2026 results on Aug 07, 2025
Reported Earnings • Jun 02Full year 2025 earnings released: EPS: ₹0.04 (vs ₹0.84 loss in FY 2024)Full year 2025 results: EPS: ₹0.04 (up from ₹0.84 loss in FY 2024). Revenue: ₹475.0m (up 20% from FY 2024). Net income: ₹1.34m (up ₹14.3m from FY 2024). Profit margin: 0.3% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 78 percentage points per year, which is a significant difference in performance.
お知らせ • May 26Jeevan Scientific Technology Limited to Report Q4, 2025 Results on May 30, 2025Jeevan Scientific Technology Limited announced that they will report Q4, 2025 results on May 30, 2025
Board Change • Apr 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 3 highly experienced directors. Independent Director Divakar Atluri was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
New Risk • Mar 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹698.8m market cap, or US$8.03m). Minor Risk Share price has been volatile over the past 3 months (8.1% average weekly change).
Reported Earnings • Feb 07Third quarter 2025 earnings released: EPS: ₹0.03 (vs ₹0.31 loss in 3Q 2024)Third quarter 2025 results: EPS: ₹0.03 (up from ₹0.31 loss in 3Q 2024). Revenue: ₹127.4m (up 26% from 3Q 2024). Net income: ₹1.05m (up ₹5.82m from 3Q 2024). Profit margin: 0.8% (up from net loss in 3Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 69 percentage points per year, which is a significant difference in performance.
お知らせ • Feb 06Jeevan Scientific Technology Limited Appoints Venkateswara Rao Ravipati as Chief Financial OfficerJeevan Scientific Technology Limited at its board meeting held on February 6, 2025, approved appointment of Mr. Venkateswara Rao Ravipati as Chief Financial Officer of the Company with effect from February 6, 2025. Mr. Venkateswara Rao Ravipati has 20+ years of experience in Accounts, Tax and Finance function. Mr. Venkateswara Rao Ravipati is a Commerce Post Graduate with 20+ years of extensive experience in finance, GST laws, Income Tax Laws, Budget Preparation, Finalization of Quarterly and Annual Accounts, Preparation of financials for Internal & Statutory Audits, Timely preparation of all Monthly, Quarterly and Annual accounts, Books of accounts maintained as per various Accounting Standards and Company policies from time to time.
お知らせ • Jan 30Jeevan Scientific Technology Limited to Report Q3, 2025 Results on Feb 06, 2025Jeevan Scientific Technology Limited announced that they will report Q3, 2025 results on Feb 06, 2025
お知らせ • Nov 27Jeevan Scientific Technology Limited Announces Cessation of G. Siva Nageswara Rao as Chief Financial OfficerJeevan Scientific Technology Limited announced the cessation of G. Siva Nageswara Rao as Chief Financial Officer of the Company with effect from November 25, 2024, due to personal reasons.
New Risk • Nov 11New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (2.3% increase in shares outstanding). Market cap is less than US$100m (₹856.5m market cap, or US$10.1m).
Reported Earnings • Nov 10Second quarter 2025 earnings released: EPS: ₹0.16 (vs ₹0.39 loss in 2Q 2024)Second quarter 2025 results: EPS: ₹0.16 (up from ₹0.39 loss in 2Q 2024). Revenue: ₹115.6m (up 43% from 2Q 2024). Net income: ₹2.39m (up ₹8.40m from 2Q 2024). Profit margin: 2.1% (up from net loss in 2Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 92 percentage points per year, which is a significant difference in performance.
お知らせ • Nov 08+ 2 more updatesJeevan Scientific Technology Limited Approves Chief Executive Officer ChangesJeevan Scientific Technology Limited at its meeting held on November 08, 2024 approved the following items of business: Resignation of Mrs. Snigdha Mothukuri as Chief Executive Officer of the Company with effect from November 08, 2024. However, she will continue as Executive Director with additional management powers and responsibilities. Appointment of Dr. Srinivas Reddy Maram as Chief Executive Officer of the Company with effect from November 08, 2024. Dr. Srinivas Reddy comes with over 26+ years of experience in Pharmaceutical Industry -- Education: Dr. Srinivas has done his MSC and PhD in Chemistry from Andhra University and also done his Senior Management program from IIM Calcutta. He has proven track record in driving business growth through strategic marketing Initiatives and financial acumen. He is expert in navigating complex regulatory environments, while implementing operational efficiencies that enhance CRO Business and product development and client engagements. He is a committed in delivering sustainable growth and elevating organizational performance through visionary leadership and strategic partnerships. He has earlier worked for organizations like Actimus Bioscience Elmira, Zydus Healthcare, lifesciences, Strides Arcolab, Dr. Reddys.
お知らせ • Nov 02Jeevan Scientific Technology Limited to Report Q2, 2025 Results on Nov 08, 2024Jeevan Scientific Technology Limited announced that they will report Q2, 2025 results on Nov 08, 2024
New Risk • Oct 04New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹837.9m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.
Reported Earnings • Aug 13First quarter 2025 earnings released: EPS: ₹0.66 (vs ₹0.33 in 1Q 2024)First quarter 2025 results: EPS: ₹0.66 (up from ₹0.33 in 1Q 2024). Revenue: ₹128.8m (up 24% from 1Q 2024). Net income: ₹10.9m (up 112% from 1Q 2024). Profit margin: 8.5% (up from 5.0% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 97 percentage points per year, which is a significant difference in performance.
お知らせ • Aug 03Jeevan Scientific Technology Limited to Report Q1, 2025 Results on Aug 09, 2024Jeevan Scientific Technology Limited announced that they will report Q1, 2025 results on Aug 09, 2024
Reported Earnings • Jun 05Full year 2024 earnings released: ₹0.86 loss per share (vs ₹2.00 loss in FY 2023)Full year 2024 results: ₹0.86 loss per share (improved from ₹2.00 loss in FY 2023). Revenue: ₹403.3m (up 12% from FY 2023). Net loss: ₹13.0m (loss narrowed 58% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 77 percentage points per year, which is a significant difference in performance.
お知らせ • May 31Jeevan Scientific Technology Limited, Annual General Meeting, Aug 09, 2024Jeevan Scientific Technology Limited, Annual General Meeting, Aug 09, 2024, at 10:00 Indian Standard Time.
お知らせ • May 23Jeevan Scientific Technology Limited to Report Q4, 2024 Results on May 30, 2024Jeevan Scientific Technology Limited announced that they will report Q4, 2024 results on May 30, 2024
お知らせ • Mar 13Jeevan Scientific Technology Limited Announces Executive Changes, Effective March 31, 2024Jeevan Scientific Technology Limited announced that Mrs. Sharvari Swapnil Shinde has resigned from the post of Company Secretary and Compliance Officer of company with effect from March 31, 2024 (After close of business hours). Mr. Krishna Kishore Kuchipudi, Managing Director of the Company will act as Compliance officer of the Company till the appointment of new Company Secretary and Compliance Officer.
Reported Earnings • Feb 15Third quarter 2024 earnings released: ₹0.31 loss per share (vs ₹0.04 profit in 3Q 2023)Third quarter 2024 results: ₹0.31 loss per share (down from ₹0.04 profit in 3Q 2023). Revenue: ₹100.1m (flat on 3Q 2023). Net loss: ₹4.77m (down ₹5.31m from profit in 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance.
お知らせ • Feb 07Jeevan Scientific Technology Limited to Report Q3, 2024 Results on Feb 14, 2024Jeevan Scientific Technology Limited announced that they will report Q3, 2024 results on Feb 14, 2024
Reported Earnings • Nov 15Second quarter 2024 earnings released: ₹0.39 loss per share (vs ₹0.83 loss in 2Q 2023)Second quarter 2024 results: ₹0.39 loss per share (improved from ₹0.83 loss in 2Q 2023). Revenue: ₹83.2m (up 4.4% from 2Q 2023). Net loss: ₹6.02m (loss narrowed 50% from 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has increased by 21% per year, which means it is well ahead of earnings.
お知らせ • Nov 05Jeevan Scientific Technology Limited to Report Q2, 2024 Results on Nov 13, 2023Jeevan Scientific Technology Limited announced that they will report Q2, 2024 results on Nov 13, 2023
New Risk • Oct 26New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹830.2m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Market cap is less than US$10m (₹830.2m market cap, or US$9.97m). Minor Risk Revenue is less than US$5m (₹362m revenue, or US$4.4m).
Reported Earnings • Aug 16First quarter 2024 earnings released: EPS: ₹0.33 (vs ₹0.26 in 1Q 2023)First quarter 2024 results: EPS: ₹0.33 (up from ₹0.26 in 1Q 2023). Revenue: ₹106.9m (up 3.5% from 1Q 2023). Net income: ₹5.15m (up 35% from 1Q 2023). Profit margin: 4.8% (up from 3.7% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 45% per year, which means it is well ahead of earnings.
お知らせ • Aug 15Jeevan Scientific Technology Limited, Annual General Meeting, Sep 29, 2023Jeevan Scientific Technology Limited, Annual General Meeting, Sep 29, 2023, at 10:30 Indian Standard Time.
お知らせ • Aug 12Jeevan Scientific Technology Limited Announces Resignation of Rama Krishna Prasad Kakarala as Non- Executive DirectorJeevan Scientific Technology Limited informed the Exchange that Mr. Rama Krishna Prasad Kakarala (DIN: 00754823), Non- Executive Director of the Company has resigned from the Board of Directors with effect from 12 August, 2023 citing the reason as personal pre occupations and commitments.
お知らせ • Aug 08Jeevan Scientific Technology Limited to Report Q1, 2024 Results on Aug 14, 2023Jeevan Scientific Technology Limited announced that they will report Q1, 2024 results on Aug 14, 2023
New Risk • Jul 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Revenue is less than US$5m (₹373m revenue, or US$4.5m). Market cap is less than US$100m (₹873.7m market cap, or US$10.6m).
Reported Earnings • Feb 09Third quarter 2023 earnings released: EPS: ₹0.04 (vs ₹2.80 in 3Q 2022)Third quarter 2023 results: EPS: ₹0.04 (down from ₹2.80 in 3Q 2022). Revenue: ₹102.3m (down 51% from 3Q 2022). Net income: ₹545.0k (down 99% from 3Q 2022). Profit margin: 0.5% (down from 20% in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has only increased by 37% per year, which means it is significantly lagging earnings growth.
お知らせ • Feb 02Jeevan Scientific Technology Limited to Report Q3, 2023 Results on Feb 08, 2023Jeevan Scientific Technology Limited announced that they will report Q3, 2023 results on Feb 08, 2023
Recent Insider Transactions • Dec 13CFO & Executive Director recently bought ₹1.1m worth of stockOn the 9th of December, Jeevan Kuchipudi bought around 18k shares on-market at roughly ₹64.97 per share. This transaction amounted to 2.9% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Jeevan's only on-market trade for the last 12 months.
Reported Earnings • Nov 16Second quarter 2023 earnings released: ₹0.83 loss per share (vs ₹2.45 profit in 2Q 2022)Second quarter 2023 results: ₹0.83 loss per share (down from ₹2.45 profit in 2Q 2022). Revenue: ₹82.8m (down 56% from 2Q 2022). Net loss: ₹11.9m (down 132% from profit in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 81% per year but the company’s share price has only increased by 41% per year, which means it is significantly lagging earnings growth.
Board Change • Nov 16High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Additional Independent Director Suryaprakasa Bommisetti was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 13Second quarter 2023 earnings released: ₹0.83 loss per share (vs ₹2.45 profit in 2Q 2022)Second quarter 2023 results: ₹0.83 loss per share (down from ₹2.45 profit in 2Q 2022). Revenue: ₹82.8m (down 56% from 2Q 2022). Net loss: ₹11.9m (down 132% from profit in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 81% per year but the company’s share price has only increased by 55% per year, which means it is significantly lagging earnings growth.
お知らせ • Nov 05Jeevan Scientific Technology Limited to Report Q2, 2023 Results on Nov 11, 2022Jeevan Scientific Technology Limited announced that they will report Q2, 2023 results on Nov 11, 2022
Valuation Update With 7 Day Price Move • Oct 10Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹69.25, the stock trades at a trailing P/E ratio of 11.8x. Average trailing P/E is 37x in the Life Sciences industry in India. Total returns to shareholders of 273% over the past three years.
お知らせ • Sep 30Jeevan Scientific Technology Limited Declares Dividend for the Financial Year Ended March 31, 2022Jeevan Scientific Technology Limited at the AGM, the shareholders declared dividend of 12% i.e., INR 1.20 per equity share of INR 10 each for the financial year ended 31st March 2022.
Upcoming Dividend • Sep 13Upcoming dividend of ₹1.20 per shareEligible shareholders must have bought the stock before 20 September 2022. Payment date: 29 October 2022. Payout ratio is a comfortable 20% and this is well supported by cash flows. Trailing yield: 1.7%. Within top quartile of Indian dividend payers (1.5%). Higher than average of industry peers (0.7%).
Valuation Update With 7 Day Price Move • Sep 06Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹63.95, the stock trades at a trailing P/E ratio of 6.5x. Average trailing P/E is 42x in the Life Sciences industry in India. Total returns to shareholders of 247% over the past three years.
Valuation Update With 7 Day Price Move • Aug 22Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₹57.95, the stock trades at a trailing P/E ratio of 5.8x. Average trailing P/E is 37x in the Life Sciences industry in India. Total returns to shareholders of 205% over the past three years.
お知らせ • Aug 13+ 2 more updatesJeevan Scientific Technology Limited Announces Executive Changes, Effective September 16, 2022Jeevan Scientific Technology Limited announced that at its board meeting held on August 12, 2022, approved the resignation of Mr. Srikanth Sasidhar Mathamsetty, Chief Financial Officer of the company with effect from September 16, 2022; approved the appointment of Mr. K. Jeevan Krishna as Chief Financial Officer of the company with effect from September 16, 2022.
お知らせ • Aug 06Jeevan Scientific Technology Limited to Report Q1, 2023 Results on Aug 12, 2022Jeevan Scientific Technology Limited announced that they will report Q1, 2023 results on Aug 12, 2022
お知らせ • Aug 05Jeevan Scientific Technology Limited Appoints Chakrapani Majumdar as Chief Operating OfficerJeevan Scientific Technology Limited appointed Mr. Chakrapani Majumdar as Chief Operating Officer of the Company with effect from 03 August 2022. Chakrapani holds Masters in Pharmaceutical Sciences with specialization in Pharmacology, Pharmaceutical Analysis and Biostatistics. Chakrapani comes with 22+ years of collective Operations and Quality Assurance experience working for various pharmaceutical companies and CROs, spanning Bioequivalence studies, Phase-1 to Phase-4 Clinical trials to techno commercial management of CROs. Chakrapani has an accomplished Quality Assurance career and rich experience of facilitating more than 50 Regulatory inspections from various regulatory bodies including USFDA, UK-MHRA, WHO ANSM, ANVISA, AGES, MCC, NPCB, GHC, DCGI etc, His success stories include, setting up of complete QMS and integration of various Global establishments of Veeda CR in India, Malaysia, Belgium, France, USA and UK.
Valuation Update With 7 Day Price Move • Jul 28Investor sentiment improved over the past weekAfter last week's 22% share price gain to ₹79.15, the stock trades at a trailing P/E ratio of 8x. Average trailing P/E is 34x in the Life Sciences industry in India. Total returns to shareholders of 266% over the past three years.
お知らせ • Jul 07Jeevan Scientific Technology Limited Announces Resignation of Srikanth Sasidhar as Chief Financial OfficerJeevan Scientific Technology Limited informed that Mr. M. Srikanth Sasidhar, CFO has vide letter dated 06.07.2022 has tendered his resignation from the post of Chief Financial Officer which is subject to the approval of the Board in its next meeting.
Valuation Update With 7 Day Price Move • Jun 03Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₹69.05, the stock trades at a trailing P/E ratio of 7x. Average trailing P/E is 32x in the Life Sciences industry in India. Total returns to shareholders of 151% over the past three years.
お知らせ • May 31Jeevan Scientific Technology Limited Recommends Final DividendJeevan Scientific Technology Limited at the Board Meeting held on 30-May-2022 the company recommended a Final Dividend of INR 1.20 per share subject to approval of members at the upcoming Annual General Meeting.
お知らせ • May 20Jeevan Scientific Technology Limited to Report Q4, 2022 Results on May 30, 2022Jeevan Scientific Technology Limited announced that they will report Q4, 2022 results on May 30, 2022
Valuation Update With 7 Day Price Move • Apr 29Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₹106, the stock trades at a trailing P/E ratio of 10.7x. Average trailing P/E is 37x in the Life Sciences industry in India. Total returns to shareholders of 247% over the past three years.
Board Change • Apr 27High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Additional Independent Director Suryaprakasa Bommisetti was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Buying Opportunity • Apr 18Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 29%. The fair value is estimated to be ₹182, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 43% over the last 3 years. Earnings per share has grown by 87%.
Valuation Update With 7 Day Price Move • Apr 06Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹156, the stock trades at a trailing P/E ratio of 15.7x. Average trailing P/E is 37x in the Life Sciences industry in India. Total returns to shareholders of 402% over the past three years.
Board Change • Apr 02High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Additional Independent Director Suryaprakasa Bommisetti was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Buying Opportunity • Mar 23Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 9.5%. The fair value is estimated to be ₹181, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 43% per annum over the last 3 years. Earnings per share has grown by 87% per annum over the last 3 years.
Valuation Update With 7 Day Price Move • Mar 14Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹144, the stock trades at a trailing P/E ratio of 14.5x. Average trailing P/E is 36x in the Life Sciences industry in India. Total returns to shareholders of 327% over the past three years.
Buying Opportunity • Feb 22Now 24% undervaluedOver the last 90 days, the stock is up 25%. The fair value is estimated to be ₹184, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 43% per annum over the last 3 years. Earnings per share has grown by 87% per annum over the last 3 years.
Valuation Update With 7 Day Price Move • Feb 21Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₹148, the stock trades at a trailing P/E ratio of 14.9x. Average trailing P/E is 37x in the Life Sciences industry in India. Total returns to shareholders of 346% over the past three years.
Reported Earnings • Feb 17Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹2.80 (down from ₹3.74 in 3Q 2021). Revenue: ₹210.2m (up 33% from 3Q 2021). Net income: ₹42.7m (down 26% from 3Q 2021). Profit margin: 20% (down from 36% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has only increased by 70% per year, which means it is significantly lagging earnings growth.
お知らせ • Feb 15Jeevan Scientific Technology Limited Approves the Change in Designation of Jeevan Krishna Kuchipudi from Non-Executive Director to Executive DirectorJeevan Scientific Technology Limited at its board meeting held on February 14, 2022 approved the Change in designation of Mr. Jeevan Krishna Kuchipudi from Non-Executive Director to Executive Director with effect from February 14, 2022.
お知らせ • Feb 05Jeevan Scientific Technology Limited to Report Q3, 2022 Results on Feb 14, 2022Jeevan Scientific Technology Limited announced that they will report Q3, 2022 results on Feb 14, 2022
Valuation Update With 7 Day Price Move • Dec 29Investor sentiment improved over the past weekAfter last week's 21% share price gain to ₹184, the stock trades at a trailing P/E ratio of 16.9x. Average trailing P/E is 33x in the Life Sciences industry in India. Total returns to shareholders of 406% over the past three years.
Valuation Update With 7 Day Price Move • Dec 14Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₹162, the stock trades at a trailing P/E ratio of 14.9x. Average trailing P/E is 32x in the Life Sciences industry in India. Total returns to shareholders of 355% over the past three years.
Valuation Update With 7 Day Price Move • Nov 25Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₹123, the stock trades at a trailing P/E ratio of 11.4x. Average trailing P/E is 28x in the Life Sciences industry in India. Total returns to shareholders of 263% over the past three years.
Reported Earnings • Nov 12Second quarter 2022 earnings released: EPS ₹2.45 (vs ₹1.79 in 2Q 2021)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2022 results: Revenue: ₹189.8m (up 55% from 2Q 2021). Net income: ₹37.4m (up 36% from 2Q 2021). Profit margin: 20% (down from 22% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has only increased by 42% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Aug 11First quarter 2022 earnings released: EPS ₹2.17 (vs ₹0.37 loss in 1Q 2021)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: ₹162.9m (up 226% from 1Q 2021). Net income: ₹33.2m (up ₹39.0m from 1Q 2021). Profit margin: 20% (up from net loss in 1Q 2021). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 47% per year whereas the company’s share price has increased by 49% per year.
Board Change • Jul 31High number of new directorsCEO & Executive Director Snigdha Mothukuri was the last director to join the board, commencing their role in 2021.
Reported Earnings • Jun 26Full year 2021 earnings released: EPS ₹7.71 (vs ₹5.61 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹493.5m (up 98% from FY 2020). Net income: ₹117.4m (up ₹203.3m from FY 2020). Profit margin: 24% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 41% per year, which means it is tracking significantly ahead of earnings growth.
Executive Departure • Jun 25CEO & Whole-Time Executive Director Rajendra Muppavarapu has left the companyDuring their tenure, earnings grew by 18% annually compared to the industry average of 9.6%. On the 23rd of June, Rajendra Muppavarapu left the company after 7.2 in the role. Rajendra still personally held 896.25k shares (₹55m worth) as of March 2021. This is 5.9% of the company. Rajendra is the only executive to leave the company over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model. Under Rajendra's leadership, the company delivered a total shareholder return of 170%.
Valuation Update With 7 Day Price Move • Jun 09Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹108, the stock trades at a trailing P/E ratio of 69.9x. Average trailing P/E is 57x in the Life Sciences industry in India. Total returns to shareholders of 214% over the past three years.
お知らせ • Feb 19Jeevan Scientific Technology Limited Announces Chief Financial Officer ChangesJeevan Scientific Technology Limited announced that Mr. Krishna Kishore Kuchipudi has resigned and ceased to be the Chief Financial Officer of the Company with effect from February 02, 2021. The company announced the appointment of Mr. M. Srikanth Sasidhar as new Chief Financial Officer on Board.
Valuation Update With 7 Day Price Move • Feb 03Investor sentiment improved over the past weekAfter last week's 27% share price gain to ₹55.70, the stock is trading at a trailing P/E ratio of 36.1x, up from the previous P/E ratio of 28.3x. This compares to an average P/E of 30x in the Life Sciences industry in India. Total returns to shareholders over the past three years are 24%.
Reported Earnings • Jan 28Third quarter 2021 earnings released: EPS ₹3.74 (vs ₹0.26 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₹160.2m (up 90% from 3Q 2020). Net income: ₹57.3m (up ₹53.4m from 3Q 2020). Profit margin: 36% (up from 4.6% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 66% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.
Is New 90 Day High Low • Jan 20New 90-day high: ₹39.15The company is up 65% from its price of ₹23.75 on 22 October 2020. The Indian market is up 23% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 15% over the same period.
お知らせ • Jan 19Jeevan Scientific Technology Limited to Report Q3, 2021 Results on Jan 27, 2021Jeevan Scientific Technology Limited announced that they will report Q3, 2021 results on Jan 27, 2021
Is New 90 Day High Low • Dec 04New 90-day high: ₹35.05The company is up 75% from its price of ₹20.05 on 04 September 2020. The Indian market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 15% over the same period.
お知らせ • Nov 25Jeevan Scientific Technology Limited Appoints Ms. Sharvari Swapnil Shinde as the Company Secretary Cum Compliance OfficerJeevan Scientific Technology Limited announced that Ms. Sharvari Swapnil Shinde has been appointed as the company secretary cum Compliance Officer of the company, with effect from November 24, 2020 and she will be responsible for all functions of a Company Secretary as prescribed under Section 203 of the Companies Act, 2013.
Is New 90 Day High Low • Nov 04New 90-day high: ₹26.55The company is up 21% from its price of ₹21.95 on 06 August 2020. The Indian market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 15% over the same period.
Is New 90 Day High Low • Oct 12New 90-day high: ₹25.25The company is up 36% from its price of ₹18.50 on 14 July 2020. The Indian market is up 10.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Life Sciences industry, which is up 39% over the same period.
Is New 90 Day High Low • Sep 24New 90-day high: ₹22.45The company is up 16% from its price of ₹19.30 on 26 June 2020. The Indian market is up 8.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Life Sciences industry, which is up 35% over the same period.
お知らせ • Sep 12Jeevan Scientific Technology Limited to Report Q4, 2020 Results on Jul 30, 2020Jeevan Scientific Technology Limited announced that they will report Q4, 2020 results on Jul 30, 2020